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Background: Recently a large number of short non-coding-RNAs (microRNAs, (miRNA)) have been identified. These
miRNAs act as post-transcriptional regulators where they generally have an inhibitory function. miRNAs are present
in all human cells, and they are also detected in serum or plasma. The miRNAs have a broad range of actions, and
their biogenesis must therefore be under tight control. One putative regulator of miRNA biogenesis or miRNA level
could be vitamin D, an ancient hormone with effects on cell growth and differentiation, apoptosis and the immune
system. In our study miRNA were reversed transcribed in total RNA isolated from plasma and analyzed by
quantitative real-time PCR (qPCR) using the miRCURY LNA Universal RT microRNA PCR system (Exiqon). In 10 pilot
subjects 136 miRNAs were detected in one or more plasma samples drawn at baseline and after 12 months of
vitamin D supplementation. The twelve miRNAs that showed the greatest change in expression in these pilots were
further analyzed by RT-qPCR of RNA from baseline and 12 months plasma samples in 40 subjects given high dose
vitamin D3 (20.000 – 40.000 IU per week) and 37 subjects given placebo.
Results: At baseline there was a significant and positive correlation between serum 25-hydroxyvitamin D and miR-
532-3p expression (r = 0.24, P = 0.04). The change in expression of miR-221 from baseline to 12 months (ddCp value)
was also significantly different between the vitamin D and placebo group (P =0.04), mainly due to a change in the
placebo group.
Conclusions: We have not been able to demonstrate a consistent effect of vitamin D supplementation on the
expression profile of miRNA in plasma. However, further studies are needed as this approach might potentially
throw light on unknown aspects of vitamin D physiology.
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It has recently been found that a large part of the human
genome is transcribed into non-coding RNAs with major
functions both in normal physiology and in pathological
processes [1,2]. One group of these non-coding-RNAs is
the small regulatory RNAs of which microRNAs (miR-
NAs) of ~22 nucleotides (nts) in size have been the most
studied [3]. So far more than1500 miRNAs have been
annotated in humans in miRBase v.18 and the number is
still increasing [4].* Correspondence: rolf.jorde@unn.no
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reproduction in any medium, provided the orThe function of miRNAs appears to be in gene regula-
tion where they act as post-transcriptional regulators.
For that purpose, a miRNA is complementary to a part
of one or more messenger RNAs (mRNAs). Perfect or
near perfect base pairing with the target RNA promotes
cleavage and destruction of the mRNA, whereas miR-
NAs that are only partially complementary to the target
may inhibit protein translation of mRNA and also cause
the mRNAs to be degraded sooner [5]. The mRNA is
thus “silenced” and the protein coded for not produced.
miRNAs therefore generally have an “inhibitory” func-
tion [6].
miRNAs are present in all human cells, are reported
to target 30 -> 60% of all protein coding genes [7,8] and
the expression profile differs from tissue to tissue [9].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ology, from cell differentiation, proliferation, and apop-
tosis [10] to the regulation of the endocrine system and
metabolism [11,12]. Over and under-expression of
miRNA appear to occur and have been linked to various
human diseases, like CNS disorders [13], vascular dis-
eases [14], viral diseases [15], diabetes [4], and in par-
ticular to cancers [16]. In general, these associations are
based on studies in tissue samples. However, such tissue
samples are not easily obtained, and it was therefore a
major step forward when it was found that miRNAs are
also detected, and remarkably stable, in serum or plasma
[17]. Furthermore, it was found that in certain diseases
like cancer and diabetes miRNAs in the serum may
serve as potential biomarkers [18-20], and the specific
serum miRNA expression profile, or a single or a couple
of miRNA(s), may constitute a fingerprint of a physio-
logical condition.
Given the broad action of miRNAs, regulation of
miRNA biogenesis must be under tight control. How-
ever, so far this has not been extensively studied, but
control mechanisms appear to operate both at transcrip-
tional and post-transcriptional levels [21]. One putative
regulator of miRNA biogenesis could be vitamin D, and
a change in vitamin D concentration could alter the level
and number of miRNAs. Vitamin D is a hormone found
in all species with a calcified skeleton. It is essential for
life in higher animals, and is the primary biological regu-
lator of calcium homeostasis [22]. The main source of
vitamin D is solar UV-radiation. Natural dietary sources
of vitamin D are few, but it is found in fat fish like sal-
mon and herring. Both dietary and solar vitamin D
undergo a hydroxylation in the liver to 25-hydroxyvita-
min D (25(OH)D) which is the biochemical marker that
best reflects the body’s vitamin D status. It serves as a
substrate for 1-α-hydroxylase in the kidneys, which
under tight regulation forms the active form of the vita-




Age (years) 43.6 ± 9.0
Smokers (%) 0 0
BMI (kg/m2) 32.0 ± 1.2 31.8 ± 1.5
Systolic blood pressure (mmHg) 128.4 ± 20.0 128.0 ± 16.7
Diastolic blood pressure (mmHg) 78.0 ± 9.0 77.8 ± 13.1
HbA1c (%) 5.56 ± 0.27 5.84 ± 0.32
Serum PTH (pmol/L) 5.54 ± 2.05 5.38 ± 1.43
Serum 25(OH)D (nmol/L) 41.5 ± 6.3 107.7 ± 7.3
Values are mean ± SD.D affects the biological activity not only in the skeleton,
but in a number of tissues [23]. It regulates key compo-
nents governing cell growth, differentiation, apoptosis
and immune system maturation [22], and low serum
levels of 25(OH)D have been associated with mortality
rate [24], cancer [25], cardiovascular diseases [26], im-
munological diseases [27], and diabetes [28]. 1,25(OH)2
D binds to a nuclear vitamin D receptor (VDR) and also
to a cell membrane receptor [22]. In a review from 2005
summarizing non-calcemic actions of vitamin D, 12
genes were identified to be up-regulated and 11 genes
down-regulated by VDR ligands [29]. As expected, most
of these genes were related to bone remodelling, cell dif-
ferentiation, metabolism and inflammation. Non-gen-
omic effects of 1,25(OH)2 D, mediated by its cell
membrane receptor, include opening of ion channels,
which leads to activation of second messengers like
PKC, PKA, and MPA kinases. These second messenger
may in turn also have effects on gene expression [30].
Considering the ancient origin of vitamin D, the recep-
tor being present in virtually all human tissue, and the
similarities between known effects of vitamin D and
conditions with altered miRNA profile, it is tempting to
speculate that vitamin D may also function as a regula-
tor of miRNA expression, which in turn may be reflected
by altered levels of miRNA in plasma. Since we have re-
cently performed intervention studies with high doses of
vitamin D, we had the opportunity to test that
hypothesis.
Results
Profiling of miRNAs in plasma from subjects given
vitamin D3
To profile miRNA in plasma from subjects before (base-
line) and 12 months after supplementation with
40.000 IU vitamin D3 per week, two pilot studies were
carried out. Their baseline and 12 months characteristics
are shown in Table 1. In the first pilot 136 miRNAs were.000 IU vitamin D3 per week in the two pilot groups
__________ Pilot group 2______________________________




31.1 ± 1.3 31.0 ± 1.3
134.2 ± 21.9 129.0 ± 10.8
81.2 ± 12.9 75.8 ± 9.0
5.74 ± 0.32 5.82 ± 0.33
5.36 ± 1.28 4.08 ± 0.95
57.8 ± 6.7 127.8 ± 16.0
Table 3 Plasma miRNAs with significant change in
expression after 1 year of 40.000 IU vitamin D3 per week
in the last five pilot subjects
miR Fold change
from baseline*
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http://www.biomedcentral.com/1756-0500/5/245detected by RT-qPCR in one or more of the samples,
and 11 miRNAs showed a significant difference in mean
expression value between baseline and 12 months (P
< 0.05, student’s t-test) (Table 2). In the second pilot 113
miRNAs were detected in one or more of the samples.
Eighteen of these miRNAs showed a significant differ-
ence in mean expression value between baseline and















*A fold change >1 indicates up regulation after 12 months, whereas a value
<1 indicates down-regulation after 12 months; **Paired t-test.Analysis of twelve selected plasma miRNAs, serum 25(OH)
D and serum PTH from subjects given vitamin D3
Two of the miRNAs were significantly different in both
pilots (miR-26a and let-7f ). These two miRNAs and
those where the difference between mean values at base-
line and after 12 months had a P value ≤ 0.02 (4 in the
first pilot and 6 in the second) were selected for the
main study.
These 12 miRNAs were analyzed by RT-qPCR in
plasma from 40 subjects given vitamin D3 (19 given
20.000 and 21 40.000 IU per week) and in 37 subjects
given placebo. The subjects given 20.000 IU and
40.000 IU vitamin D3 per week are presented as one
vitamin D group. The baseline and 12 months character-
istics of the vitamin D and placebo groups are given in
Table 4. As expected, the group given vitamin D had a
substantial increase in serum 25(OH)D and a significant
decrease in serum PTH levels, which was not seen in
the placebo group.
Two of the 12 selected miRNAs (miR-19a and miR-
548b-3p) were detected in only a few of the samples due
to low expression and not included in the following
presentation. At baseline there were no significant differ-
ences between the two groups regarding the expression
of the miRNAs. In the placebo group there was aTable 2 Plasma miRNAs with significant change in
expression after 1 year of 40.000 IU vitamin D3 per week
in the first five pilot subjects
miR Fold change
from baseline*













*A fold change >1 indicates up regulation after 12 months, whereas a value
<1 indicates down-regulation after 12 months; **Paired t-test.significant (P = 0.03) decrease in median miR-221 ex-
pression from 0.02 at baseline to – 0.28 after 12 months,
and the change in miR-221 expression from baseline to
12 months (ddCp value) was also significantly different
between the two groups (P = 0.04) (Table 5). There were
no other significant changes for any of the other miR-
NAs in any of the two groups. At baseline there was a
significant and positive correlation between serum 25
(OH)D and miR-532-3p expression (r = 0.24, P = 0.04).
There were no correlations between serum 25(OH)D
and miRNAs regarding changes from baseline to
12 months.
Discussion
To our knowledge this is the first report on potential ef-
fect of vitamin D on miRNA profile in plasma. At base-
line we found a significant but weak correlation between
miR-532-3p expression and serum 25(OH)D that was
most probably due to chance. Furthermore, there was a
difference between the placebo group and the vitamin D
group regarding change in miR-221 expression from
baseline to 12 months, but this was due to a reduction
in miR-221 in the placebo group whereas that miRNA
was unchanged in the vitamin D group. Accordingly, we
were not able to demonstrate any consistent and truly
significant effect of vitamin D on the miRNA plasma
profile.
Table 4 Characteristics at baseline and after 12 months in the vitamin D and placebo group
Vitamin D group*______________________________ Placebo group______________________________
Baseline 12 months Baseline 12 months
N 40 40 37 37
Age (years) 48.9 ± 10.0 51.0 ± 10.1
Smokers (%) 20.0 18.9
BMI (kg/m2) 34.4 ± 4.2 34.5 ± 4.5 34.3 ± 3.1 34.5 ± 3.5
Systolic blood pressure (mmHg) 130.7 ± 13.6 136.2 ± 16.9 130.9 ± 16.1 131.6 ± 16.6
Diastolic blood pressure (mmHg) 81.5 ± 10.8 84.1 ± 10.5 79.4 ± 10.5 80.3 ± 8.9
HbA1c (%) 5.62 ± 0.40 5.74 ± 0.40 5.74 ± 0.42 5.80 ± 0.46
Serum PTH (pmol/L) 5.63 ± 1.60 4.64 ± 1.55a 5.79 ± 1.81 5.66 ± 2.06
Serum 25(OH)D (nmol/L) 50.2 ± 14.2 101.7 ± 17.8a 53.0 ± 19.1 49.6 ± 16.0
*19 subjects given 20.000 IU and 21 subjects given 40.000 IU vitamin D3 per week.
a P <0.01 versus baseline in the vitamin D group and versus 12 months values
in the placebo group; t-tests. Values are mean± SD
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Ideally, we would have preferred to do a complete
miRNA profiling by RT-qPCR in all the 77 subjects, but
for financial reasons that was not possible. An additional
factor was that inclusion of 100–150 miRNAs would
have made it very difficult to evaluate whether an
observed change was truly significant or simply due to
chance because of a large number of miRNA analyzed.
Instead we did two pilot studies and included the 12
most promising miRNAs. Two of these miRNAs had
shown a significant expression change from baseline to
12 months in both pilot studies and an additional ten
miRNAs had shown a significant change with P ≤ 0.02 in
one of the pilot studies. We therefore anticipated that
we could reproduce a significant effect of vitamin D for
at least a few of these miRNAs. Since information is
available on which gene(s) the miRNAs are targeting this
could potentially disclose new aspects of vitamin D’s role
in biology.
However, we could not reproduce the findings from
the pilot studies, nor did we find any new consistent cor-
relations. For this there could be a number of reasons.
First of all, we might have analyzed the “wrong” miR-
NAs. Although there are no previous reports on effect of
vitamin D supplementation on plasma or serum miRNA
profile, there are reports on effects of vitamin D on cel-
lular miRNA expression. Thus, in a prostate cancer cell
line (LNcaP) 15 miRNAs were either up- or down-regu-
lated by 1,25(OH)2D [31]. Among these 15 miRNAs,
only miR-22, which was up-regulated, was included in
our analysis. Furthermore, in a study on early pregnancy
where RNA had been extracted and purified from whole
blood, women with low versus high serum 25(OH)D
levels had different expression of 11 miRNAs [32]. How-
ever, none of these eleven miRNAs were among those
analyzed by us. And finally, in a study on breast epithe-
lial cells, 25(OH)D was found to protect against cellular
stress, which might be mediated by altered expression offive miRNAs [33]. But again, none of these miRNAs
were analysed in our study.
Secondly, the amount of miRNA in plasma is often
low as demonstrated by the number of cycles needed be-
fore detection in the RT-qPCR assay. We observed vari-
ation in the expression profiles of miRNAs between first
and second pilot study (e.g. between baselines) and in
the expression of individual miRNA both in the baseline
and 12 months samples. Normal biological variation of
miRNA levels in plasma together with variation intro-
duced during sample treatments (from blood sampling
to RT-qPCR) may affect the observed expression of miR-
NAs [34]. Also in the initial report on miRNA in serum,
most of the miRNAs were detected in both serum and
blood cells. However, only a small number of miRNAs
were uniquely present in either serum or blood cells, in-
dicating that under normal conditions most serum miR-
NAs are derived from circulating blood cells [17].
Accordingly, in our subjects, who were healthy apart
from their overweight, an effect of vitamin D might not
be easily detected. Furthermore, most of our subjects
had normal serum 25(OH)D levels, and it is plausible
that an effect of vitamin D is most evident in vitamin D
deficiency. It should also be considered that an effect of
vitamin D could have been present at an earlier time
point than 12 months, and as the effect of vitamin D
may be U-shaped [24], lower doses of vitamin D3 might
also have been more effective.
On the other hand, our study also has some strength.
We included a large group of subjects, and the vitamin
D doses given were high and the resulting serum 25
(OH)D levels were in the upper physiological range [22].
In addition, the miRCURY LNA RT-qPCR system used
for detection of known plasma miRNAs has been found
to be more sensitive and reproducible than microarray
systems and show even more sensitivity and linearity
than TaqMan methods at low concentration of plasma
miRNA [35,36].
Table 5 miRNA expression. Average expression values at baseline, after 12 months and average expression change from baseline (delta values) in the vitamin
D and placebo groups













let-7f 0.14(−0.06, 0.39) 0.29(−0.10, 0.45) 0.11(−0.38, 0.37) 0.10(−0.05, 0.30) 0.11(−0.12, 0.29) −0.12(−0.34, 0.22)
let-7a 1.09(0.86, 1.18) 1.06(0.88, 1.27) 0.07(−0.15, 0.26) 0.94(0.82, 1.17) 1.02(0.81, 1.19) 0.06(−0.23, 0.23)
miR-151-5p −0.88(−1.12, -0.68) −0.90(−1.08, -0.66) 0.04(−0.26, 0.24) −0.92(−1.24, -0.76) −1.14(−1.35, -0.78) −0.12(−0.47, 0.17)
miR-22 −0.81(−1.13, -0.57) −0.91(−1.17, -0.56) −0.09(−0.38, 0.29) −0.72(−1.12, -0.49) −0.79(−0.97, -0.48) −0.04(−0.19, 0.25)
miR-221 0.03(−0.32, 0.29) 0.09(−0.21, 0.27) 0.13(−0.21, 0.29) 0.02(−0.27, 0.26) −0.28(−0.58, 0.10) −0.32(−0.53, 0.10)
miR-26a 2.07(1.90, 2.24) 2.09(1.81, 2.25) −0.02(−0.29, 0.26) 1.94(1.70, 2.11) 1.83(1.53, 2.15) −0.05(−0.39, 0.25)
miR-28-5p −4.10(−4.51, -3.66) −4.11(−4.48, -3.71) 0.09(−0.60, 0.53) −4.14(−4.63, -3.93) −4.30(−4.55, -3.95) −0.14(−0.76, 0.32)
miR-532-3p −4.80(−5.05, -4.37) −4.68(−4.84, -4.25) 0.06(−0.46, 0.63) −4.66(−5,21, 4.24) −4.63(−5.03, -4.27) 0.19(−0.45, 0.42)
miR-766 −3.53(−3.97, -3.30) −3.59(−4.01, -3.32) −0.11(−0.39, 0.39) −3.68(−4.00, -3.41) −3.72(−4.14, -3.44) −0.10(−0.39, 0.18)
miR-99b −3.42(−3.61, -3.12) −3.34(−3.73, -3.04) 0.03(−0.42, 0.27) −3.43(−3.75, -3.14) −3.42(−3.91, -3.23) 0.04(−0.33, 0.20)
*19 subjects given 20.000 IU and 21 subjects given 40.000 IU vitamin D3 per week.
a Average difference in expression values (average expression at 12 months minus average expression at baseline); b P = 0.03 vs
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In conclusion, we have not been able to demonstrate an
effect of vitamin D supplementation on the miRNA
plasma profile expression. However, further studies are
needed as this approach might potentially throw light on
unknown aspects of vitamin D physiology.Methods
Selection of subjects, study design and blood sampling
Plasma samples used in the pilot and main study were
all randomly selected from a previous study where we
evaluated the effect of high doses of vitamin D supple-
mentation (20.000 IU or 40.000 IU vitamin D3 per week)
versus placebo for one year on weight reduction in obese
subjects [37]. Only males were included in the present
study, all subjects were generally in good health, and
none had diabetes or any other serious concomitant dis-
eases. Fasting blood samples were drawn at baseline and
after 12 months at the end of the study. Blood for
plasma preparation was collected using a 19-gauge nee-
dle into vacutainers (Becton Dickinson, Meylan Cedex,
France) containing 0.129 M sodium citrate (1 volume
anticoagulant and 9 volumes whole blood) as anticoagu-
lant, centrifuged at 2000 g for 15 minutes at 22°C, trans-
ferred into sterile cryovials in aliquots of 1 ml and
stored at −70°C until further analysis.Figure 1 Box chart showing the experimental design.To identify miRNAs potentially affected by vitamin
D supplementation, two pilot studies each including
plasma samples from five subjects given 40.000 IU
vitamin D3 were performed. The most promising miR-
NAs were then selected and baseline and 12 months
plasma samples analysed in 40 subjects given vitamin
D3 (19 given 20.000 IU and 21 40.000 IU per week) and
37 subjects given placebo. A box chart showing the ex-
perimental design is presented in Figure 1.RNA isolation, reverse transcription and quantitative
real-time PCR
All the total RNA isolations and real-time qPCR
experiments were performed by “Exiqon Services”,
Vedbaek, Denmark. Total RNA was isolated from
200 μl plasma samples using the QIAGEN miRNeasy
Mini Kit Protocol (Quiagen) slightly modified by
Exiqon (http://www.exiqon.com/ls/Documents/Scientific/
serum-plasma-RNA-isolation.pdf) with elution in 50 μl
DNase/RNase-free water. Two μl of total RNA was reverse
transcribed in 10 μl reactions using the miRCURY LNA™
Universal RT miRNA PCR, Polyadenylation and cDNA
synthesis kit (Exiqon). Four ul of cDNA diluted 50 x
(equivalent to 0.064 μl original plasma sample), was
assayed in 10 ul PCR reactions according to the protocol
for miRCURY LNA™ Universal RT miRNA PCR. DNA and
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respectively. Negative controls, without enzymes, from the
reverse transcription reaction was treated and profiled like
the samples. All amplifications were performed in a
LightCyclerW 480 Real-Time PCR System (Roche) in 384
well plates.
In the two pilots studies plasma samples from baseline
and after 12 months were analyzed for presence of
miRNA. Each cDNA sample was assayed once by qPCR
on the microRNA Ready-to-Use PCR, Human panel I
and panel II containing 730 miRNAs (first pilot) and 742
mRNAs (second pilot).
In the main study plasma from the 77 subjects were
analysed for expression of 12 miRNAs (let-7a, let-7f,
miR-19a, miR-22, miR26a, miR28-5p, miR-99b, miR151-
5p, miR-221, miR-532-3p, miR-548-3p, miR-766). Each
plasma sample was processed in singlicates and each
cDNA (miRNA) sample was assayed once by qPCR.
Data pre-processing
Determination of Cp values and the generation of
amplification- and melting curves were performed by
use of the The LightCyclerW 480 software. Amplifica-
tion efficiency was determined by the LinRegPCR
(ver 11.5) software. All assays were inspected for dis-
tinct melting curves and Tm was checked to be
within known specifications for the assay. Only
assays detected with 5Cp’s less than the negative con-
trol and with Cp< 37 were included in the data ana-
lysis. Data that did not pass these criteria were
omitted from any further analysis. The average amp-
lification efficiency was used to correct the Raw Cp
values. For the pilot studies NormFinder found the
geomean of miRNAs detected in all samples to be
the best normalizer. All data was normalized to the
geomean using the formula Normalized Cp =Geo-
mean (n = 10) – assay Cp. For the main study the
data was normalized based on the geomean Cp of
the reference miRNAs miR-30a, miR-103, miR-191,
miR-320a and miR-423-5p, on a well-to-well basis.
The efficiency corrected Cps of the five reference
miRNAs in each plasma sample are given in the
Additional file 1: Table S1.
Other analyses
Height and weight, blood pressure, serum parathyroid
hormone (PTH) and 25(OH)D were measured/analyzed
as previously described [37].
Statistical analyses
Normal distribution was evaluated with kurtosis and
skewness and visual inspection of histograms. The vari-
ables age, BMI, blood pressure, serum PTH and 25(OH)
D were normally distributed whereas several of themiRNAs were not. As these miRNAs also included nega-
tive numbers, logarithmic transformation was not pos-
sible. Therefore, non-parametric statistics were used for
the miRNAs. Comparisons between the vitamin D group
and the placebo group were done with student’s t-test or
Mann–Whitney U- test, and within each group with
paired student’s t-test or Wilcoxon signed rank test. Cor-
relations were evaluated with Spearman’s rho. When
comparing the effects of vitamin D versus placebo after
12 months, the ddCp values were used (value at
12 months minus value at baseline). The data are pre-
sented as mean ± SD or median (25, 75 percentile). All
tests were done two-tailed and P< 0.05 was considered
statistically significant. The P-values are presented with-
out correction for multiple testing.
Ethics
The study was approved by the Regional Committee for
Medical and Health Research Ethics, North Norway
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Additional file 1: Table S1. A sheet containing the efficiency corrected
Cps of the reference miRNAs.
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